These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

718 related items for PubMed ID: 16225526

  • 1. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002).
    Vela-Navarrete R, Gonzalez-Enguita C, Garcia-Cardoso JV, Manzarbeitia F, Sarasa-Corral JL, Granizo JJ.
    BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526
    [Abstract] [Full Text] [Related]

  • 2. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M, Eaddy MT, Hogue SL, Kruep EJ, Shah MB.
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [Abstract] [Full Text] [Related]

  • 3. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM.
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
    Agha AH, Roy JB, Culkin DJ, Lyon K.
    Adv Ther; 1995 Apr; 12(6):361-6. PubMed ID: 10163332
    [Abstract] [Full Text] [Related]

  • 8. Contemporary patients with LUTS/BPH requiring prostatectomy have long-term history of treatment with alpha1-blockers and large prostates compared with past cases.
    Takeuchi M, Masumori N, Tsukamoto T.
    Urology; 2009 Sep; 74(3):606-9. PubMed ID: 19586655
    [Abstract] [Full Text] [Related]

  • 9. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
    Roehrborn CG.
    BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
    [Abstract] [Full Text] [Related]

  • 10. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
    Marberger M.
    Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
    [Abstract] [Full Text] [Related]

  • 11. Long-term results of medical treatment in benign prostatic hyperplasia.
    Kim CI, Chang HS, Kim BK, Park CH.
    Urology; 2006 Nov; 68(5):1015-9. PubMed ID: 17095071
    [Abstract] [Full Text] [Related]

  • 12. Clinical and economic outcomes in patients treated for enlarged prostate.
    Naslund MJ, Issa MM, Grogg AL, Eaddy MT, Black L.
    Am J Manag Care; 2006 Mar; 12(4 Suppl):S111-6. PubMed ID: 16551204
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of high-energy transurethral microwave thermotherapy in alleviating medically refractory urinary retention due to benign prostatic hyperplasia.
    Kellner DS, Armenakas NA, Brodherson M, Heyman J, Fracchia JA.
    Urology; 2004 Oct; 64(4):703-6. PubMed ID: 15491705
    [Abstract] [Full Text] [Related]

  • 14. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression.
    Trachtenberg J.
    BJU Int; 2005 Jun; 95 Suppl 4():6-11. PubMed ID: 15871730
    [Abstract] [Full Text] [Related]

  • 15. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG.
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [Abstract] [Full Text] [Related]

  • 16. [Benign hypertrophy of the prostate: which treatment, for whom?].
    Schulman C.
    Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
    [Abstract] [Full Text] [Related]

  • 17. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 18. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997.
    Sarma AV, Jacobson DJ, McGree ME, Roberts RO, Lieber MM, Jacobsen SJ.
    J Urol; 2005 Jun; 173(6):2048-53. PubMed ID: 15879823
    [Abstract] [Full Text] [Related]

  • 19. Diagnosis and management of benign prostatic hyperplasia.
    Edwards JL.
    Am Fam Physician; 2008 May 15; 77(10):1403-10. PubMed ID: 18533373
    [Abstract] [Full Text] [Related]

  • 20. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G, Emberton M, Alcaraz A, Matzkin H, van Moorselaar RJ, Hartung R, Harving N, Elhilali M, ALF-ONE Study Group.
    BJU Int; 2008 Apr 15; 101(7):847-52. PubMed ID: 18321317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.